In this CardiaCast episode, Kevin M. Alexander, MD is joined by Sarah Cuddy, MBBCh, to discuss the latest clinical data for investigational therapies and available treatments for transthyretin amyloid cardiomyopathy (ATTR-CM), as well as the potential implications of these findings on clinical practice and future clinical studies. First, they will explore results from CARDIO-TTRansform, the phase 3 trial of eplontersen in ATTR-CM, followed by the results from REVEAL, the phase 3 trial using radiotracer I-124 evuzamitide to detect cardiac amyloidosis. Next, they will discuss recently published studies describing the extracardiac effects of available therapies for ATTR-CM, specifically those describing the effects of acoramidis on kidney function and the effects of vutrisiran on gastrointestinal events.

This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology.

Related References:

1. Alexander KM. Durable survival benefits of acoramidis over 54 months in variant transthyretin amyloid cardiomyopathy (ATTR-CM), including p.V142I: interim findings from ATTRibute-CM and its open-label extension. Presented at: the European Society of Cardiology Congress; Munich, Germany; August 30, 2026.
2. Dorbala S, Maurer MS, Cuddy SAM, et al. 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial. JAMA. Published online August 30, 2026. doi:10.1001/jama.2026.17361
3. Fontana M, Masri A, Solomon SD, et al. Eplontersen for Transthyretin Amyloid Cardiomyopathy. N Engl J Med. Published online August 28, 2026. doi:10.1056/NEJMoa2608510
4. Testani JM, Judge DP, Borlaug BA, et al. Effects of Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2026;19(8):e014656. doi:10.1161/CIRCHEARTFAILURE.126.014656
5. Urey MA, Bui QM, Obici L, et al. Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study. Amyloid. Published online July 17, 2026. doi:10.1080/13506129.2026.2695367